SecBot SecBot

IPHA

Innate Pharma SA
Nasdaq· Biological Products, (No Diagnostic Substances)· Inc. I0· CIK 0001598599 Biotech & Drug Discovery
$1.54 +0.04 (+2.67%)
Oct 26 4:00 PM ET · prev $1.50
Market cap
$167.6M
Micro cap
Consensus
Buy
86% Buy or better · 7 analysts
Median target
$7.00
+355% · range $4.00–9.00
1 year
−35.3%
from $2.38 · Oct 27
30 days
−9.4%
from $1.70
52-week range
$1.17–2.54
−39% from high · low Mar 20
Avg volume 20D
35.4K
Oct 6 spike 133.7K
Short interest
88.6K
≈0.1% of shares · +16.5%
Days to cover
1.3
at average volume
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
11
analyzed by SecBot
SecBot read BULLISH 10 reports · 90 days
Balance 0 bearish · 3 bullish · 1 mixed · 6 neutral oldest → newest, height = score
Avg score ·High conf. 9/10
Strongest BULLISH Innate Pharma reported H1 2026 financial results showing a net loss of €19.6M (improved from €21.3M loss in…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InstitutionsMIXED

    Q2 2026: 2 added (0 new), 1 trimmed or exited.

  • AnalystsBULLISH

    6 of 7 rate it Buy or better. Every target is above the price.

  • EstimatesFALLING

    Current-quarter EPS estimate −$0.138 → −$0.150 over 90 days. 0 up, 1 down in 30 days.

  • Short sellersBUILDING

    Short interest +16.5% to 88.6K shares. 1.3 days to cover, ≈0.1% of shares.

  • TrendDOWNTREND

    15% below its 50-day average.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
JANE STREET GROUP, LLCNEAR_EXIT10,310$19.0K
UBS Group AGADD1,363$2.5K
Farther Finance Advisors, LLCDOUBLED21$38.00
JANE STREET GROUP, LLCTRIM43,365$55.5K
MILLENNIUM MANAGEMENT LLCTRIM10,064$12.9K
RHUMBLINE ADVISERSDOUBLED5,204$9.1K
UBS Group AGNEAR_EXIT947$1.7K
BARCLAYS PLCNEAR_EXIT1$2.00

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

7 analysts
Buy 86% rate it Buy or better
Strong Buy2Buy4Hold1Sell0Strong Sell0
12-month targets · 3 analysts

Price is below the lowest target. Median implies +355%.Targets as of Oct 26, 2026.

Recent actions
DateFirmActionRating
Sep 17, 2026BTIG
REITERATE
REITERATEBuy
Aug 12, 2026BTIG
MAINTAIN
MAINTAINBuy
Aug 10, 2026HC Wainwright & Co.
MAINTAIN
MAINTAINBuy

Earnings setup

Estimates
−$0.15
EPS estimate, this quarter
−9%
estimate change, 90 days
0↑ 1↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.15-$0.15–-$0.15-114.3%$2.3M
Next Q-$0.28-$0.28–-$0.28-295.7%$2.3M
Current FY-$0.18-$0.53–$0.16-106.9%$44.2M
Next FY-$0.47-$0.50–-$0.45+25.3%$107.4M
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Sep 16, 2026
Contract
Sobi and Innate announce partnership is now effective following completion of closing conditions
STOCKHOLM, Sept. 16, 2026 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) and Innate Pharma SA (Euronext Paris: IPH) (NASDAQ: IPHA)…
Aug 10, 2026
Contract
Sobi enters strategic partnership with Innate Pharma to license lacutamab in T-cell lymphoma
STOCKHOLM, Aug. 10, 2026 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) and Innate Pharma SA (Euronext Paris: IPH) (NASDAQ: IPHA)…
May 14, 2026
Clinical Trial
Study on the Anti-tumor Activity, Safety and Pharmacology of IPH2101 in Patients With Smoldering Multiple Myeloma
Phase 2 · COMPLETED
Apr 14, 2026
Clinical Trial
Phase1/2 Study of IPH6501 in Patients With Relapsed /Refractory B-Cell Non-Hodgkin Lymphoma
Phase 2 · TERMINATED

Short side

FINRA· Sep 30, 2026
88,622
shares short
+16.5%
vs prior settlement
1.3
days to cover
≈0.1%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 21, 2026 SEC
Innate Pharma announced management participation in the Stifel Healthcare Conference (Nov 10-12, 2026) and Jefferies…
6-K — Impact 2/10
Oct 20, 2026 SEC
Innate Pharma filed a 6-K announcing a conference call on November 5, 2026, to provide a business and financial update…
6-K — Impact 2/10
Sep 17, 2026 SEC
Innate Pharma reported H1 2026 financial results showing a net loss of €19.6M (improved from €21.3M loss in H1 2025)…
6-K — Impact 7/10
Sep 16, 2026 Press
Innate Pharma's strategic partnership with Sobi for lacutamab is now effective after closing conditions were met…
Impact 6/10
Sep 16, 2026 Contract
Sobi and Innate announce partnership is now effective following completion of closing conditions
STOCKHOLM, Sept. 16, 2026 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) and Innate Phar
Jun 30, 2026 Inst.
JANE STREET GROUP, LLC — NEAR_EXIT
10,310 shares ($19.0K)
Jun 30, 2026 Inst.
UBS Group AG — ADD
1,363 shares ($2.5K)

SecBot reports

11 filings · 1 press release · 2 bullish · 0 bearish · 2 mixed · 7 neutral
All IPHA filing & press-release reports (12)